Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Study of Cofrogliptin in Type 2 Diabetes Mellitus
ChiCTR2600128851Phase 4Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cofrogliptin in type 2 diabetes mellitus (T2DM), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: HbA1c at 24 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
cofrogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2600128851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128851.